The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in this setting.
Panelists discuss how graft-vs-host disease (GVHD) is a complex immune-mediated condition, highlighting the differences between acute and chronic GVHD, the associated risk factors, prognosis, and…
One of the goals of the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program at Dana-Farber Cancer Institute is to provide resources and information to…
Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report.…
The U.S. Food and Drug Administration and the U.S. Department of Health and Human Services Office of Human Research Protections issued Draft Guidance on the…
W. Kimryn Rathmell has stepped down as NCI director, opting to hand her resignation to the Biden administration over facing the uncertainties that Trump and…
Royal jelly is a bee product, but it has many differences from honey. Here’s how royal jelly is made, the nutrients it contains and what…
Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.
About 3.7 million people are at immediate risk of losing health coverage should the federal government cut funding for Medicaid expansions, as some allies of…
Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.
Latest News The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (CALQUENCE) for Mantle Cell Lymphoma January 16, 2025 – On January 16,
